---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-095577"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2023-08-28T23:59:59+00:00"
generated_at: "2026-06-11T03:09:54.476871+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Apogee Therapeutics Q2 net loss $18.9M; $345M IPO funds runway into 4Q26

## Summary
- Raised $345M in upsized July IPO; cash balance $125.1M at June 30; projected runway into 4Q 2026.
- Phase 1 trial of APG777 initiated; initial safety/PK data expected mid-2024.
- Appointed Mark McKenna Chairman, Matt Batters General Counsel, Rebecca Dabora CTO.
- Net loss Q2 2023 $18.9M vs $1.8M in Q2 2022; R&D expenses rose to $13.9M.
- APG808 development candidate selected expected Q4 2023; APG990 candidate in 2024.

## SEC filing metadata
- accession: 0001104659-23-095577
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2023-08-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000110465923095577/0001104659-23-095577-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000110465923095577/tm2324402d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-095577
- JSON: https://secwatch.observer/filing/0001104659-23-095577.json
- Plain text: https://secwatch.observer/filing/0001104659-23-095577.txt

## Key facts
- Earnings Releases
  Apogee Therapeutics, Inc. reported financial results for second quarter 2023.
  - Period: second quarter 2023
  - Result: reported results
  source text: On August 28, 2023, Apogee Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1974640/000110465923095577/0001104659-23-095577-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.